A new 14-year study of 148,739 women with type 2 diabetes (mean age of 63.3 years) showed an overall 18% reduced breast cancer risk for women who used low-dose aspirin daily compared to those who did not after adjusting for confounders. The authors of the Journal of Women’s Healthstudy reported that a high cumulative dose of aspirin over the 14-year study period reduced breast cancer risk by 47%. A cumulative aspirin dosage of >88,900 mg was associated with a reduced risk of breast cancer in women with type 2 diabetes, though additional studies are necessary to confirm the findings.